NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

免疫性血小板減少性疾病(ITP)- 流行病學預測 2028年

Immune Thrombocytopenia (ITP) - Epidemiology Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 915396
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
免疫性血小板減少性疾病(ITP)- 流行病學預測 2028年 Immune Thrombocytopenia (ITP) - Epidemiology Forecast-2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的免疫性血小板減少性疾病(ITP)2017年的患病數估算為2,662萬1,142人。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的免疫性血小板減少性疾病(ITP)調查,疾病概要和流行病學的預測,各性別、各國患病數及診斷數的變化與預測等資訊。

目錄

第1章 重要洞察

第2章 免疫性血小板減少性疾病(ITP)患者概要

  • 患者分佈(實在數值)
  • 患者分佈(預測值)

第3章 免疫性血小板減少性疾病(ITP):疾病背景和概要

  • 簡介
  • 病因
  • 症狀
  • 種類
  • 病理生理學
  • 遺傳性背景和環境要素
  • 相關生物標記
  • 診斷
  • 診斷指南

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的免疫性血小板減少性疾病(ITP)的總患病數
  • 主要7個國家的免疫性血小板減少性疾病(ITP)的診斷患病數

第5章 免疫性血小板減少性疾病(ITP)流行病學:各國

  • 美國
    • 假設和根據
    • 總患病數
    • 診斷患病數
    • 診斷患病數:性別
  • 歐盟5國
    • 德國
      • 假設和根據
      • 總患病數
      • 診斷患病數
      • 診斷患病數:性別
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第6章 附錄

  • 調查手法

第7章 DelveInsight的服務內容

第8章 免責聲明

第9章 關於DelveInsight

目錄
Product Code: DIEI0386

DelveInsight's 'Immune Thrombocytopenia (ITP) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the ITP, historical and forecasted epidemiology as well as the ITP trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Immune Thrombocytopenia (ITP) Disease Understanding

Immune Thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of ITP stem from a low platelet count leading to excessive bleeding. In severe cases, frequent bleeding episodes may result in low levels of circulating red blood cells (anemia), which may cause fatigue and impair response to exertion. In rare cases, serious bleeding into the brain (intracranial hemorrhage) may occur.

The two main types of ITP are acute (short term) and chronic (long term). ITP is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).

Immune Thrombocytopenia (ITP) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of ITP, Total Diagnosed Prevalent Population of ITP, and Gender-specific Diagnosed Prevalent Population of ITP scenario of ITP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Immune Thrombocytopenia (ITP) Detailed Epidemiology Segmentation

  • Assessments as per DelveInsight's analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.
  • DelveInsight's estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017.
  • The total diagnosed prevalent cases in the 7MM was estimated to be approximately 147,174 in 2017.
  • In 2017, there were around 63,725 prevalent cases and approximately 53,362 diagnosed prevalent cases of ITP in the United States. Out of the total diagnosed cases, approximately 49,640 cases account for adult ITP and approximately 3,723 cases were diagnosed prevalence population in children in 2017 in the United States.
  • Japan had 27,005 prevalent cases of ITP in 2017.
  • Among the European countries, the United Kingdom had the highest prevalent population of ITP with approximately 26,274 cases, followed by Italy which had a prevalent population of approximately 18,604 in 2017. On the other hand, Spain had the lowest prevalent population of approximately 12,207 cases in 2017.

Scope of the Report:

  • The report covers the descriptive overview of ITP, explaining its causes, signs and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of ITP.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Population of ITP, Total Diagnosed Prevalent Population of ITP, and Gender-specific Diagnosed Prevalent Population of ITP.

Report Highlights:

  • 11-Year Forecast of ITP
  • 7MM Coverage
  • Total Prevalent Population of ITP
  • Total Diagnosed Prevalent Population of ITP
  • Gender-specific Diagnosed Prevalent Population of ITP

Key Questions Answered

  • What is the disease risk, burden and unmet needs of ITP?
  • What is the historical ITP patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of ITP at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ITP?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of ITP during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to buy:

The ITP report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM ITP epidemiology forecast.
  • The ITP epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The ITP epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1. Key Insights

2. Executive Summary of Immune Thrombocytopenia

3. SWOT Analysis for Immune Thrombocytopenia

4. Immune Thrombocytopenia (ITP) Epidemiology Overview at a Glance

  • 4.1. Epidemiology Share (%) Distribution of Immune Thrombocytopenia (ITP) in 2017
  • 4.2. Epidemiology Share (%) Distribution of Immune Thrombocytopenia (ITP) in 2030

5. Immune Thrombocytopenia (ITP): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Etiology of Immune Thrombocytopenia (ITP)
  • 5.3. Signs and Symptoms of Immune Thrombocytopenia (ITP)
  • 5.4. Types of Immune Thrombocytopenia (ITP)
  • 5.5. Pathophysiology of Immune Thrombocytopenia (ITP)
  • 5.6. Pathogenesis of Immune Thrombocytopenia (ITP)
  • 5.7. Genetic background and environmental factors related to ITP
  • 5.8. Biomarkers associated with Immune Thrombocytopenia (ITP)
  • 5.9. Diagnosis of Immune Thrombocytopenia
  • 5.10. Diagnostic Guidelines of Immune Thrombocytopenia
    • 5.10.1. 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
    • 5.10.2. The American Society of Hematology 2011 evidence-based practice guideline for Immune Thrombocytopenia
    • 5.10.3. Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura
    • 5.10.4. Spanish Society of Hematology and Hemotherapy: Guidelines for diagnosis, treatment and monitoring of the PTI

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Prevalent Patient Population of Immune Thrombocytopenia (ITP)
  • 6.3. 7MM Diagnosed Prevalent Patient Population of Immune Thrombocytopenia

7. Country Wise-Epidemiology of Immune Thrombocytopenia (ITP)

  • 7.1. United States Epidemiology
    • 7.1.1. Assumptions and Rationale
    • 7.1.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in the United States
    • 7.1.3. Diagnosed Prevalence of Immune Thrombocytopenia in the United States
    • 7.1.4. Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in the United States
  • 7.2. EU5 Epidemiology
    • 7.2.1. Germany
      • 7.2.1.1. Assumptions and Rationale
      • 7.2.1.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Germany
      • 7.2.1.3. Diagnosed Prevalence of Immune Thrombocytopenia in Germany
      • 7.2.1.4. Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany
    • 7.2.2. France
      • 7.2.2.1. Assumptions and Rationale
      • 7.2.2.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in France
      • 7.2.2.3. Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in France
      • 7.2.2.4. Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in France
    • 7.2.3. Italy
      • 7.2.3.1. Assumptions and Rationale
      • 7.2.3.2. Total Prevalent Cases of Immune Thrombocytopenia in Italy
      • 7.2.3.3. Diagnosed Prevalence of Immune Thrombocytopenia in Italy
      • 7.2.3.4. Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy
    • 7.2.4. Spain
      • 7.2.4.1. Assumptions and Rationale
      • 7.2.4.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Spain
      • 7.2.4.3. Diagnosed Prevalence of Immune Thrombocytopenia in Spain
      • 7.2.4.4. Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain
    • 7.2.5. United Kingdom
      • 7.2.5.1. Assumptions and Rationale
      • 7.2.5.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in the United Kingdom
      • 7.2.5.3. Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom
      • 7.2.5.4. Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom
  • 7.3. Japan Epidemiology
    • 7.3.1. Assumptions and Rationale
    • 7.3.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Japan
    • 7.3.3. Diagnosed Prevalence of Immune Thrombocytopenia in Japan
    • 7.3.4. Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in Japan

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1 Summary of ITP Epidemiology, and Key Events (2017-2030)
  • Table 2 The role of infections in ITP pathogenesis
  • Table 3 Idiopathic Thrombocytopenic Purpura in Children: Newly Diagnosed ITP
  • Table 4 Total Prevalent Patient Population of Immune Thrombocytopenia in the7MM (2017-2030)
  • Table 5 Diagnosed Prevalent Patient Population of Immune Thrombocytopenia in the 7MM (2017-2030)
  • Table 6 Total Prevalent Population of Immune Thrombocytopenia in the United States (2017-2030)
  • Table 7 Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2030)
  • Table 8 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United States (2017-2030)
  • Table 9 Total Prevalent Population of Immune Thrombocytopenia in Germany (2017-2030)
  • Table 10 Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2030)
  • Table 11 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2030)
  • Table 12 Total Prevalent Population of Immune Thrombocytopenia in France (2017-2030)
  • Table 13 Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2030)
  • Table 14 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2030)
  • Table 15 Total Prevalent Population of Immune Thrombocytopenia in Italy (2017-2030)
  • Table 16 Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2030)
  • Table 17 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2030)
  • Table 18 Total Prevalent Population of Immune Thrombocytopenia in Spain (2017-2030)
  • Table 19 Diagnosed Prevalence of Immune Thrombocytopenia in Spain (2017-2030)
  • Table 20 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain (2017-2030)
  • Table 21 Total Diagnosed Prevalent Population of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2030)
  • Table 22 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2030)
  • Table 23 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2030)
  • Table 24 Total Prevalent Population of Immune Thrombocytopenia (ITP) in Japan (2017-2030)
  • Table 25 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2030)
  • Table 26 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2030)

List of Figures

  • Figure 1 SWOT Analysis for Immune Thrombocytopenia
  • Figure 2 Differences in B cell and T cell mechanisms in immune thrombocytopenia (ITP)
  • Figure 3 Signs and Symptoms of Immune Thrombocytopenia
  • Figure 4 Classification of Immune Thrombocytopenia (ITP)
  • Figure 5 ITP International Working Group proposed definitions of disease
  • Figure 6 Pathophysiology of cITP
  • Figure 7 Cellular pathogenic mechanisms in immune thrombocytopenia
  • Figure 8 Immune thrombocytopenia pathogenesis
  • Figure 9 Total Prevalent Patient Population of Immune Thrombocytopenia in 7MM (2017-2030)
  • Figure 10 Diagnosed Prevalent Patient Population of Immune Thrombocytopenia in the 7MM (2017-2030)
  • Figure 11 Total Prevalent Cases of Immune Thrombocytopenia in the United States (2017-2030)
  • Figure 12 Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2030)
  • Figure 13 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2030)
  • Figure 14 Total Prevalent Cases of Immune Thrombocytopenia in Germany (2017-2030)
  • Figure 15 Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2030)
  • Figure 16 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2030)
  • Figure 17 Total Prevalent Cases of Immune Thrombocytopenia in France (2017-2030)
  • Figure 18 Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2030)
  • Figure 19 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2030)
  • Figure 20 Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2030)
  • Figure 21 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2030)
  • Figure 22 Total Prevalent Cases of Immune Thrombocytopenia in Spain (2017-2030)
  • Figure 23 Diagnosed Prevalence of Immune Thrombocytopenia in Spain (2017-2030)
  • Figure 24 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain (2017-2030)
  • Figure 25 Total Prevalent Cases of Immune Thrombocytopenia in the United Kingdom (2017-2030)
  • Figure 26 Diagnosed Prevalence of Immune Thrombocytopenia in the United Kingdom (2017-2030)
  • Figure 27 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in the United Kingdom (2017-2030)
  • Figure 28 Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Japan (2017-2030)
  • Figure 29 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2030)
  • Figure 30 Gender-specific Diagnosed Prevalence of Immune Thrombocytopenia in Japan (2017-2030)